{"slug":"omron","name":"옴론","name_en":"Omron","ticker":"6645.T","updated_at":"2026-07-12T04:02:58.465+00:00","canonical":"https://valuechain.wiki/omron","kicker":"닛케이 225 · 산업 자동화 · 혈압계 세계 1위","kicker_en":"Nikkei 225 · industrial automation · No.1 in BP monitors","lead":"산업 자동화 제어기기(IAB)와 가정용 혈압계 헬스케어를 양대 축으로 하는 일본 전자기업이다. IAB는 반도체·2차전지 설비의 센서·컨트롤러 수요를 잡는 최우선 성장 사업이고, 헬스케어는 가정용 혈압계 세계 1위로 누적 4억 대를 넘겼다.","lead_en":"A Japanese electronics maker built on two pillars: industrial-automation controls (IAB) and home healthcare led by blood pressure monitors. IAB, its top growth priority, rides sensor and controller demand from semiconductor and EV-battery plants, while healthcare holds the world No.1 spot in home BP monitors with 400 million-plus units sold.","segments":{"fy":2026,"parts":[{"name":"산업자동화 IAB ¥440bn 계획"},{"name":"헬스케어 HCB ¥150bn 계획"},{"name":"소셜시스템 SSB ¥153bn 계획"},{"name":"데이터솔루션 DSB(JMDC)"}],"total":"¥767.4bn (FY2025 계속사업, +7.3%)","concentration":"IAB가 최우선 성장축(반도체·2차전지 설비투자, 생성형 AI 수요). 부품 사업 DMB는 2026년 매각(중단사업). 가정용 혈압계 세계 1위."},"segments_en":{"fy":2026,"parts":[{"name":"Industrial Automation IAB ~¥440bn plan"},{"name":"Healthcare HCB ~¥150bn plan"},{"name":"Social Systems SSB ~¥153bn plan"},{"name":"Data Solutions DSB (JMDC)"}],"total":"¥767.4bn (FY2025 continuing ops, +7.3%)","concentration":"IAB is the top growth axis (semiconductor & secondary-battery capex on generative-AI demand). Components arm DMB divested in 2026 (discontinued op). No.1 in home blood pressure monitors."},"returns_yearly":{"2021":-9.3,"2022":-9,"2023":-8.8,"2024":-22,"2025":-21.9,"2026":55.2},"return_asof":"2026-07-10","value_chain":{"leading":[],"benefiting":[],"analysis":"옴론의 논지는 반도체·2차전지 설비투자에 연동되는 산업 자동화(IAB)와 방어적인 헬스케어 현금흐름의 결합이다. IAB는 반도체·EV 배터리 제조 라인에 센서·컨트롤러·안전기기를 대는 최우선 성장 사업으로, 생성형 AI發 반도체·배터리 캐파 투자가 수요를 끈다 — 2025년 -22% 뒤 2026년 반등은 이 설비 사이클의 회복을 반영한다. 반대편에는 가정용 혈압계 세계 1위(누적 4억 대·점유 약 39%)라는 사이클 무관 현금창출원이 있고, 2023년 JMDC 인수로 데이터솔루션(DSB)을 더해 의료데이터 시너지를 넓혔다. 원가단은 반도체(MCU)·원자재·물류·미국 관세에 노출돼 마진을 압박하며, 부품 사업(DMB)은 2026년 매각으로 자동화·헬스케어에 집중한다. 재평가 트리거는 반도체·2차전지 설비 사이클, 원가·관세 완화, 그리고 JMDC 데이터 매출의 성장이다.","analysis_en":"Omron's thesis is the pairing of industrial automation (IAB) tied to semiconductor and EV-battery capex with defensive healthcare cash flow. IAB — its top growth priority — supplies sensors, controllers and safety gear to semiconductor and EV-battery lines, with generative-AI-driven chip and battery capacity investment pulling demand; the 2026 rebound after -22% in 2025 reflects a recovery in that capex cycle. On the other side sits a cycle-agnostic cash generator: No.1 in home blood-pressure monitors (400M+ cumulative units, ~39% share), broadened by the 2023 JMDC acquisition that added the Data Solutions (DSB) segment and medical-data synergies. On the cost side it is exposed to semiconductors (MCUs), raw materials, logistics and US tariffs that pressure margin, while the components arm (DMB) was divested in 2026 to focus on automation and healthcare. Re-rating triggers are the semiconductor/EV-battery capex cycle, easing costs and tariffs, and growth in JMDC data revenue.","analysis_asof":"2026-07-10"},"edges":[{"direction":"revenue","counterparty":"반도체·2차전지 등 제조 설비 (FA 제어·센서)","counterparty_slug":null,"confidence":"high","metric":{"type":"segment_sales","unit":"JPY bn","as_of":"2026-05","basis":"연결 실적 자료","value":440,"period":"IAB FY2026 계획","basis_en":"consolidated results materials"},"note":"반도체·2차전지(EV 배터리) 등 제조 라인에 센서·컨트롤러·안전기기 같은 FA 제어기기를 공급한다. 생성형 AI發 반도체·배터리 설비투자가 수요를 견인하며, IAB는 옴론 최우선 성장 사업(FY2026 매출 계획 약 ¥440bn).","note_en":"Supplies FA control gear — sensors, controllers, safety — to manufacturing lines, notably semiconductor and secondary-battery (EV) plants. Generative-AI-driven semiconductor and battery capex fuels demand; IAB is Omron's top-priority growth segment (FY2026 sales plan ~¥440bn).","sources":[{"stance":"confirms","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2026-05-13","url":"https://www.omron.com/global/en/assets/file/ir/irlib/20260513_financial_results.pdf","title":"2026년 3월기 연결 실적 요약 (US GAAP)","title_en":"Summary of Consolidated Financial Results for the Year Ended March 31, 2026 (U.S. GAAP)","excerpt":"\"차기(2027년 3월기)에도 생성형 AI 수요에 힘입어 산업자동화 사업과 연계된 반도체·2차전지 분야 설비투자가 연중 강세를 유지할 것으로 본다\"; IAB는 회사의 최우선 전략 사업.","excerpt_en":"\"We expect capital investment in the semiconductor-related and secondary battery areas in connection with the Industrial Automation Business to remain strong throughout the year, supported by demand related to generative AI\"; IAB is the Company's highest strategic priority."},{"stance":"confirms","publisher":"마켓스크리너","publisher_en":"MarketScreener","kind":"research","lang":"en","published_at":"2026-05-01","url":"https://www.marketscreener.com/quote/stock/OMRON-CORPORATION-6491550/consensus/","title":"옴론(6645) 애널리스트 컨센서스·투자의견","title_en":"Omron (6645) Analyst Consensus & Recommendations","excerpt":"애널리스트 컨센서스 투자의견은 '매수'; 옴론은 PLC·릴레이·센서·스위치 등 공장자동화 제어기기 시장의 선도 업체.","excerpt_en":"Analyst consensus rating is Buy; Omron is a leading player in factory-automation control equipment (PLCs, relays, sensors, switches)."},{"stance":"confirms","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2025-07-01","url":"https://www.omron.com/global/en/integrated_report/strategybusiness/iab/","title":"통합보고서 2025 — 산업자동화 사업(IAB)","title_en":"Integrated Report 2025 — Industrial Automation Business (IAB)","excerpt":"옴론 현장 엔지니어가 반도체·EV 등 고정밀 제어가 요구되는 고객 현장에 투입되며, 설비 상태 감시용 각종 센서와 고속·고정밀 제어 컨트롤러가 핵심 제품이다.","excerpt_en":"Omron field engineers deploy at customer sites in advanced fields such as semiconductors and EVs where high-precision control is required; sensors for equipment monitoring and high-speed, high-precision controllers are its core products."}]},{"direction":"revenue","counterparty":"소비자·약국·의료기관 (혈압계·건강기기)","counterparty_slug":null,"confidence":"high","metric":{"type":"share","unit":"%","as_of":"2025","basis":"시장조사","value":39.4,"period":"글로벌 혈압계","basis_en":"market research"},"note":"가정용 혈압계 세계 1위(누적 4억 대 돌파, 130여 개국 유통, 글로벌 점유율 약 39%)로 혈압계·네뷸라이저·심전계 등을 소비자·약국·의료기관에 판매한다. FY2026 매출 계획 약 ¥150bn.","note_en":"World No.1 in home blood pressure monitors (400M+ cumulative units, 130+ countries, ~39% global share), selling BP monitors, nebulizers and ECGs to consumers, pharmacies and clinics. FY2026 sales plan ~¥150bn.","sources":[{"stance":"mentions","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2026-05-13","url":"https://www.omron.com/global/en/assets/file/ir/irlib/20260513_financial_results.pdf","title":"2026년 3월기 연결 실적 요약 (US GAAP)","title_en":"Summary of Consolidated Financial Results for the Year Ended March 31, 2026 (U.S. GAAP)","excerpt":"\"핵심 제품인 혈압계 시장 매출은 중국을 제외한 전 지역에서 견조하게 유지됐다.\"","excerpt_en":"\"Sales in the market for blood pressure monitors, our core product, remained steady in all areas with the exception of China.\""},{"stance":"confirms","publisher":"한국오므론헬스케어","publisher_en":"Omron Healthcare Korea","kind":"ir","lang":"ko","published_at":"2025-10-01","url":"https://www.omron-healthcare.co.kr/newsroom/all/view?bbsSq=432","title":"가정용 혈압계 글로벌 누적 판매량 4억 대 돌파","title_en":"OMRON home blood pressure monitors pass 400M cumulative units","excerpt":"가정용 혈압계 글로벌 누적 판매량이 4억 대를 돌파했다(1973년 출시, 2009년 1억 대 달성 이후 가속).","excerpt_en":"OMRON's cumulative global sales of home blood pressure monitors surpassed 400 million units (launched 1973, 100M by 2009, accelerating since)."},{"stance":"confirms","publisher":"옴론 헬스케어","publisher_en":"Omron Healthcare","kind":"ir","lang":"en","published_at":"2025-09-29","url":"https://healthcare.omron.com/press-releases/omron-healthcare-exceeds-400m-blood-pressure-monitors-sold","title":"옴론 헬스케어, 혈압계 누적 판매 4억 대 돌파","title_en":"OMRON Healthcare Exceeds 400M Blood Pressure Monitors Sold","excerpt":"\"옴론 혈압계 전 세계 누적 판매량이 2025년 9월 29일 기준 4억 대를 돌파했다\"; 130여 개국 유통.","excerpt_en":"\"Cumulative worldwide sales of OMRON blood pressure monitors have exceeded 400 million units as of September 29, 2025\"; distributed in 130+ countries."},{"stance":"confirms","publisher":"포춘 비즈니스 인사이트","publisher_en":"Fortune Business Insights","kind":"research","lang":"en","published_at":"2025-06-01","url":"https://www.fortunebusinessinsights.com/industry-reports/blood-pressure-monitors-market-100059","title":"혈압계 시장 점유율 리포트 — 옴론 최대","title_en":"Blood Pressure Monitors Market Share Report — Omron leads","excerpt":"옴론은 세계 혈압계 시장 최대 점유율(약 39.4%)을 보유한다.","excerpt_en":"Omron holds the largest share of the global blood pressure monitor market (~39.4%)."}]},{"direction":"cost","counterparty":"원자재·물류·에너지","counterparty_slug":null,"confidence":"high","metric":{"qualifier":"confirmed_no_disclosed_value"},"note":"원자재가 급등·물류비 상승·미국 관세가 매출총이익률을 압박했다(FY2025 원가 요인). 글로벌 생산·조달의 비용 축이며, 회사는 판가 조정과 공급망 강건화로 대응한다고 밝혔다.","note_en":"Soaring raw-material prices, higher logistics costs and US tariffs pressured gross margin (FY2025 cost drivers) — the cost axis of global production and procurement, which the Company addresses via price adjustments and more resilient supply-chain management.","sources":[{"stance":"confirms","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2026-05-13","url":"https://www.omron.com/global/en/assets/file/ir/irlib/20260513_financial_results.pdf","title":"2026년 3월기 연결 실적 요약 (US GAAP)","title_en":"Summary of Consolidated Financial Results for the Year Ended March 31, 2026 (U.S. GAAP)","excerpt":"\"원자재가 급등, 물류비 상승, 미국 관세 정책의 영향으로 매출총이익률이 하락했다.\"","excerpt_en":"\"A decline in gross profit margin stemming from soaring raw materials prices, rising logistics costs, and the impact of the U.S. tariff policy.\""},{"stance":"mentions","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2025-05-08","url":"https://www.omron.com/global/en/assets/file/ir/irlib/20250508_financial_results.pdf","title":"2025년 3월기 연결 실적 요약 (US GAAP)","title_en":"Summary of Consolidated Financial Results for the Year Ended March 31, 2025 (U.S. GAAP)","excerpt":"회사는 판가 조정과 더 강건한 공급망 관리로 관세·비용 변동에 대응하겠다고 밝혔다.","excerpt_en":"The Company said it would respond to tariff and cost swings through selling-price adjustments and more resilient supply-chain management."}]},{"direction":"investment","counterparty":"JMDC (의료데이터 자회사 인수)","counterparty_slug":null,"confidence":"high","metric":{"qualifier":"confirmed_no_disclosed_value"},"note":"2023년 10월 JMDC를 연결 자회사로 편입해 데이터솔루션(DSB)을 신설하고, 산업자동화·헬스케어·소셜시스템 사업에 의료·건강 데이터 시너지를 확장했다.","note_en":"Made JMDC a consolidated subsidiary in October 2023, creating the Data Solutions segment (DSB) and extending medical/health-data synergies across industrial automation, healthcare and social-systems businesses.","sources":[{"stance":"confirms","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2026-05-13","url":"https://www.omron.com/global/en/assets/file/ir/irlib/20260513_financial_results.pdf","title":"2026년 3월기 연결 실적 요약 (US GAAP)","title_en":"Summary of Consolidated Financial Results for the Year Ended March 31, 2026 (U.S. GAAP)","excerpt":"데이터솔루션 사업은 JMDC를 축으로 제약사·보험사 대상 데이터 거래를 확대하고 있다.","excerpt_en":"The Data Solutions business, centered on JMDC, is expanding data transactions with pharmaceutical and insurance companies."},{"stance":"confirms","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2025-05-08","url":"https://www.omron.com/global/en/assets/file/ir/irlib/20250508_financial_results.pdf","title":"2025년 3월기 연결 실적 요약 (US GAAP)","title_en":"Summary of Consolidated Financial Results for the Year Ended March 31, 2025 (U.S. GAAP)","excerpt":"\"JMDC는 2023년 10월 16일 연결 자회사가 되었다\"; DSB는 2024년 3월기 3분기에 신설된 세그먼트.","excerpt_en":"\"JMDC, Inc. became a consolidated subsidiary on October 16, 2023\"; DSB is a segment newly established in Q3 of the year ended March 2024."}]},{"direction":"revenue","counterparty":"제약사·보험사 (익명 의료데이터·JMDC)","counterparty_slug":null,"confidence":"mid","metric":{"qualifier":"confirmed_no_disclosed_value"},"note":"데이터솔루션(DSB)의 JMDC가 건강보험조합·의료기관에서 나온 익명 의료데이터와 'Pep Up' 건강정보 플랫폼을 제약사·보험사에 제공한다. 거래 지속 증가.","note_en":"Under Data Solutions (DSB), JMDC provides anonymized medical data from health-insurance associations and institutions plus the 'Pep Up' health platform to pharmaceutical and insurance companies; transactions keep rising.","sources":[{"stance":"confirms","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2026-05-13","url":"https://www.omron.com/global/en/assets/file/ir/irlib/20260513_financial_results.pdf","title":"2026년 3월기 연결 실적 요약 (US GAAP)","title_en":"Summary of Consolidated Financial Results for the Year Ended March 31, 2026 (U.S. GAAP)","excerpt":"\"건강보험조합·의료기관에서 나온 익명 데이터를 활용하는 제약사·보험사와의 거래가 계속 증가했다\"; Pep Up 발급 ID 증가.","excerpt_en":"\"Transactions also continued to increase with pharmaceutical companies and insurance companies that use anonymous data originating from health insurance associations and medical institutions\"; Pep Up IDs rose."}]},{"direction":"cost","counterparty":"반도체·전자부품 (MCU·센서 IC 등)","counterparty_slug":null,"confidence":"mid","metric":{"qualifier":"confirmed_no_disclosed_value"},"note":"PLC·컨트롤러·센서 제조에 필요한 반도체(MCU)·전자부품을 매입한다. 원가의 핵심 축으로 반도체 수급·원자재가 상승에 노출된다.","note_en":"Buys semiconductors (MCUs) and electronic components to build its PLCs, controllers and sensors — a core cost axis exposed to chip supply and raw-material inflation.","sources":[{"stance":"mentions","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2026-05-13","url":"https://www.omron.com/global/en/assets/file/ir/irlib/20260513_financial_results.pdf","title":"2026년 3월기 연결 실적 요약 (US GAAP)","title_en":"Summary of Consolidated Financial Results for the Year Ended March 31, 2026 (U.S. GAAP)","excerpt":"원자재가 급등 등으로 매출총이익률이 하락했다(부품·소재 조달 원가 압박).","excerpt_en":"Gross profit margin declined on soaring raw-material prices, reflecting pressure on component and material procurement costs."},{"stance":"confirms","publisher":"옴론(공식 IR)","publisher_en":"Omron (Official IR)","kind":"filing","lang":"en","published_at":"2025-07-01","url":"https://www.omron.com/global/en/integrated_report/strategybusiness/iab/","title":"통합보고서 2025 — 산업자동화 사업(IAB)","title_en":"Integrated Report 2025 — Industrial Automation Business (IAB)","excerpt":"옴론 IAB의 핵심 제품인 센서·컨트롤러는 반도체·전자부품을 내장한다(제조 투입).","excerpt_en":"Omron IAB's core sensors and controllers embed semiconductors and electronic components as manufacturing inputs."}]}]}